L. Costantino

发表

Soft docking and multiple receptor conformations in virtual screening.

B. Shoichet, A. Ferrari, BinQing Wei, 2004, Journal of medicinal chemistry.

Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?

G. Biagini, A. Torsello, C. Marinelli, 2014, Current medicinal chemistry.

Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.

G. Tosi, F. Forni, M. Vandelli, 2005, Journal of controlled release : official journal of the Controlled Release Society.

Privileged Structures as Leads in Medicinal Chemistry

Daniela Barlocco, Luca Costantino, L. Costantino, 2006 .

Privileged structures as leads in medicinal chemistry.

Daniela Barlocco, Luca Costantino, L. Costantino, 2006, Current medicinal chemistry.

Drug delivery to the CNS and polymeric nanoparticulate carriers.

L. Costantino, 2010, Future medicinal chemistry.

PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid.

G. Tosi, M. Vandelli, L. Costantino, 2010, Biomaterials.

Chapter 3 - Colloidal systems for CNS drug delivery.

B. Ruozi, G. Tosi, F. Forni, 2009, Progress in brain research.

Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.

Maria Angela Vandelli, Robert Gurny, Luca Costantino, 2006, Biomaterials.

Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy

E. Leo, L. Costantino, C. Rustichelli, 2018, Drug Delivery and Translational Research.

Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

L. Costantino, R. Maccari, R. Ottanà, 2002, Bioorganic & medicinal chemistry.

Current and Future Chemotherapy for Chagas Disease.

Maria Paola Costi, Terry K. Smith, J. McKerrow, 2015, Current Medicinal Chemistry.

New perspectives on the development of antiobesity drugs.

L. Costantino, D. Barlocco, 2015, Future medicinal chemistry.

Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase.

G. Rastelli, L. Costantino, S. Benvenuti, 1992, Planta medica.

Synthesis of Novel Benzoic Acid Derivatives with Benzothiazolyl Subunit and Evaluation as Aldose Reductase Inhibitors

L. Costantino, B. Matuszczak, D. Rakowitz, 2005, Archiv der Pharmazie.

Magnetic and optical bistability in tetrairon(III) single molecule magnets functionalized with azobenzene groups.

A. Barra, L. Costantino, P. Neugebauer, 2012, Dalton transactions.

In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?

C. Siligardi, E. Leo, L. Costantino, 2020, Nanomaterials.

Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy.

M. A. Croce, E. Leo, L. Costantino, 2017, International journal of pharmaceutics.

Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors

R. Glennon, L. Costantino, Carol Smith, 2000 .

Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors.

R. Glennon, L. Costantino, Carol Smith, 2000, Drug and alcohol dependence.

An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis.

L. Chiarelli, M. Mori, F. Meneghetti, 2019, Current topics in medicinal chemistry.

Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process.

G. Rastelli, L. Costantino, D. Garland, 1998, Biochemistry.

Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.

Maria Paola Costi, S. Gul, L. Costantino, 2018, European journal of medicinal chemistry.

Inhibitory activity of flavonols towards the xanthine oxidase enzyme

G. Rastelli, L. Costantino, A. Albasini, 1992 .

Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.

G. Tosi, M. Vandelli, L. Costantino, 2009, Nanomedicine : nanotechnology, biology, and medicine.

Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.

L. Costantino, G. Grella, G. Pinna, 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Drugs/lamellae interface influences the inner structure of double-loaded liposomes for inhaled anti-TB therapy: An in-depth small-angle neutron scattering investigation.

M. Mori, F. Meneghetti, C. Castellano, 2019, Journal of colloid and interface science.

Ghrelin receptor modulators and their therapeutic potential.

L. Costantino, D. Barlocco, 2009, Future medicinal chemistry.

Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders.

W. Ong, L. Costantino, Suku-Maran Shalini, 2014, Current medicinal chemistry.

Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

G. Rastelli, L. Costantino, P. Vianello, 1999, Medicinal research reviews.

New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications

G. Rastelli, L. Costantino, P. Vianello, 1997 .

Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase

G. Rastelli, L. Costantino, P. Vianello, 1997 .

Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors.

G. Rastelli, L. Costantino, P. Vianello, 1999, Journal of medicinal chemistry.

Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.

G. Rastelli, L. Costantino, P. Vianello, 1996, Journal of medicinal chemistry.

Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study.

A. Ferrari, G. Rastelli, L. Costantino, 2002, Bioorganic & medicinal chemistry.

Discovery of new inhibitors of aldose reductase from molecular docking and database screening.

Maria Cristina Gamberini, Giulio Rastelli, Luca Costantino, 2002, Bioorganic & medicinal chemistry.

On the prodrug potential of novel aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure.

L. Costantino, B. Matuszczak, D. Rakowitz, 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacological approaches to the treatment of diabetic complications

G. Rastelli, L. Costantino, D. Barlocco, 2000 .

SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent.

Maria Paola Costi, S. Gul, G. Ponterini, 2019, ACS medicinal chemistry letters.

Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin

G. Rastelli, L. Costantino, A. Albasini, 1995 .

Structural bases for the inhibition of aldose reductase by phenolic compounds.

G. Rastelli, L. Costantino, S. Benvenuti, 2000, Bioorganic & medicinal chemistry.

Teaching an Undergraduate Organic Chemistry Laboratory Course with a Tailored Problem-Based Learning Approach

Daniela Barlocco, Luca Costantino, L. Costantino, 2019, Journal of Chemical Education.

Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.

Maria Paola Costi, S. Gul, G. Ponterini, 2019, European journal of medicinal chemistry.

PABA-ALGINATE COMPLEX AS SUNSCREEN AGENT

L. Costantino, N. Sala, V. Iannuccelli, 2003 .

A rational approach to the design of flavones as xanthine oxidase inhibitors

G. Rastelli, L. Costantino, A. Albasini, 1996 .

Synthesis and activity of a new series of chalcones as aldose reductase inhibitors

L. Costantino, S. Benvenuti, L. Antolini, 1998 .

1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.

G. Rastelli, A. Iannone, L. Costantino, 1999, Journal of medicinal chemistry.

Nanoparticles for drug delivery to the CNS

B. Ruozi, G. Tosi, F. Forni, 2008 .

New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies

L. Chiarelli, M. Mori, F. Meneghetti, 2018, Molecules.

Oxidative Modification of Aldose Reductase Induced by Copper Ion

G. Rastelli, A. Scaloni, L. Costantino, 2002, The Journal of Biological Chemistry.

Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase.

L. Costantino, O. Livi, I. Giorgi, 1996, Journal of Medicinal Chemistry.

Synthesis and Biological Evaluation of New Imidazole, Pyrimidine, and Purine Derivatives and Analogues as Inhibitors of Xanthine Oxidase.

L. Costantino, O. Livi, I. Giorgi, 1996 .

Synthesis and biological activity of pyrimido[2,1-b][1,3]thiazine, [1,3]thiazino[3,2-a]purine and [1,2,3]triazolo[4,5-d][1,3]thiazino[3,2-a]pyrimidine derivatives and thiazole analogues.

L. Costantino, M. Portolani, C. Cermelli, 1991, Farmaco.

Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?

L. Costantino, D. Boraschi, 2012, Drug discovery today.

STAT 3 as a target for cancer drug discovery.

L. Costantino, D. Barlocco, 2008, Current medicinal chemistry.

Physico-chemical properties of anthocyanidins. Part 1. Theoretical evaluation of the stability of the neutral and anionic tautomeric forms

Giulio Rastelli, Luca Costantino, G. Rastelli, 1993 .

Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.

C. Laggner, T. Langer, P. Paoli, 2009, Bioorganic & medicinal chemistry.

Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.

Maria Paola Costi, R. Wade, S. Gul, 2016, Journal of medicinal chemistry.

Isolation and pharmacological activities of the Tecoma stans alkaloids.

L. Costantino, D. Barlocco, L. Raimondi, 2003, Farmaco.

Polymeric nanoparticles for the drug delivery to the central nervous system

Barbara Ruozi, Maria Angela Vandelli, Luca Costantino, 2008, Expert opinion on drug delivery.

Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluation

L. Costantino, 2012, Expert opinion on therapeutic patents.

Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.

Maria Paola Costi, Ulrike Wittig, S. Gul, 2019, Journal of medicinal chemistry.

Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.

Maria Paola Costi, S. Gul, L. Costantino, 2017, European journal of medicinal chemistry.

Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles.

G. Tosi, F. Forni, M. Vandelli, 2005, Biomaterials.

Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents.

L. Chiarelli, M. Mori, F. Meneghetti, 2018, European journal of medicinal chemistry.

Folate: Relevance of Chemical and Microbial Production

S. Raimondi, L. Costantino, M. Rossi, 2016 .

Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.

M A Vandelli, F Forni, G Tosi, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Designing Approaches to Multitarget Drugs

Daniela Barlocco, Luca Costantino, L. Costantino, 2017 .

7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study.

G. Rastelli, L. Costantino, A. Del Corso, 2001, European journal of medicinal chemistry.

Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.

M A Vandelli, F Forni, G Tosi, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.

Luca Costantino, Diana Boraschi, Paola Italiani, 2012, Nanomedicine.

Theoretical and experimental study of flavones as inhibitors of xanthine oxidase

G. Rastelli, L. Costantino, A. Albasini, 1995 .

Synthesis and description of chalcone-like compounds, inhibitors of aldose reductase

A. Mucci, L. Costantino, S. Benvenuti, 1996 .

Inhibition of lens aldose reductase by biflavones from Ouratea spectabilis.

L. Costantino, E. Gonçalez, J. D. Felício, 1995, Planta medica.

Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?

Daniela Barlocco, Luca Costantino, L. Costantino, 2013, Future medicinal chemistry.

A Model of the Interaction of Substrates and Inhibitors with Xanthine Oxidase

G. Rastelli, L. Costantino, A. Albasini, 1997 .

Solvent effects on the tautomerism of apigeninidin

G. Rastelli, L. Costantino, A. Albasini, 1994 .

Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery

Maria Paola Costi, R. Wade, W. Hunter, 2017, ACS omega.

Growth hormone secretagogue receptor antagonists

L. Costantino, 2012, Expert opinion on therapeutic patents.

Ghrelin receptor modulators: a patent review (2011 – 2014)

L. Costantino, D. Barlocco, 2014, Expert opinion on therapeutic patents.

Methods for synthesis and uses of inhibitors of Ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetes

L. Costantino, 2010, Expert Opinion on Therapeutic Patents.

Determination of drug-macromolecule binding parameters by numerical analysis

L. Costantino, A. Albasini, M. Cevolani, 1991 .

Challenges in the design of clinically useful brain-targeted drug nanocarriers.

L. Costantino, D. Boraschi, M. Eaton, 2014, Current Medicinal Chemistry.

Ten Years of Medicinal Chemistry (2005-2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Public-Private Partnerships.

L. Costantino, D. Barlocco, 2016, Journal of medicinal chemistry.

Synthesis and Aldose Reductase Inhibitory Activity of a New Series of Benzo[h]cinnolinone Derivatives.

G. Rastelli, L. Costantino, D. Barlocco, 2001 .

Iron Acquisition Pathways as Targets for Antitubercular Drugs.

L. Chiarelli, F. Meneghetti, S. Villa, 2016, Current medicinal chemistry.

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents

L. Chiarelli, M. Mori, F. Meneghetti, 2019, Journal of enzyme inhibition and medicinal chemistry.

The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant

C. Siligardi, E. Leo, L. Costantino, 2019, Pharmaceutics.

Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH.

G. Rastelli, L. Costantino, A. Del Corso, 2000, Experimental eye research.

2'-Deoxyuridine 5'-monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivatives.

Maria Paola Costi, S. Mangani, L. Costantino, 2013, Journal of medicinal chemistry.

Inhibitors for proteins endowed with catalytic and non-catalytic activity which recognize pTyr.

L. Costantino, D. Barlocco, 2004, Current medicinal chemistry.

Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth

E. Giovannetti, G. Peters, R. Wade, 2022, eLife.

Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors

Maria Paola Costi, L. Costantino, J. Blázquez, 2017, Medicinal Chemistry Research.

Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.

G. Tosi, M. Vandelli, L. Costantino, 2009, Nanomedicine : nanotechnology, biology, and medicine.

Ghrelin receptor modulators: a patent review (2011 – 2014)

L. Costantino, D. Barlocco, 2014, Expert opinion on therapeutic patents.

Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.

L. Costantino, D. Boraschi, P. Italiani, 2012, Nanomedicine.